Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

Joshua Boger Biography and Net Worth

Director of Vertex Pharmaceuticals

Joshua Boger, Ph.D. is the founder of Vertex Pharmaceuticals, a biopharmaceutical company based in Boston. He has developed multiple drugs and is considered a pioneer in the field of structure-based rational drug design.

Dr. Boger founded Vertex in 1989, and he retired as CEO 20 years later in 2009. He continued to serve on the board until 2017, chairing its science and technology committee.

Before Vertex, he held the position of senior director of basic chemistry at Merck Sharp & Dohme Research Laboratories in Rahway, New Jersey, where he led the departments of biophysical chemistry and medicinal chemistry of immunology and inflammation.

Dr. Boger launched his industry career at Merck, and during his tenure there, he developed a global reputation for the application of computer modeling to the chemistry of drug design and was a pioneer in the use of structure-based rational drug design as the basis for drug discovery programs. He is also known for setting up alliances between pharmaceutical companies and disease-focused foundations, resulting in the commercialization of the first drug to treat the genetic defect associated with cystic fibrosis.

Dr. Boger has also held the roles of executive chairman, board director, and chairman of the board for organizations including Bio (The Biotechnology Innovation Organization), Alkeus Pharmaceuticals, and Millennium Pharmaceuticals.

He is the author of more than 50 scientific publications and holds 32 U.S. patents in pharmaceutical development and discovery.

Dr. Boger is involved in multiple philanthropic efforts in the Boston area, focused on performing arts, science, social justice, and education. He sits on the boards of various organizations, including the Greater Boston Food Bank, the Boston Museum of Science, the Harvard Medical School board of fellows, and the Celebrity Series of Boston.

He earned his B.A. in chemistry and philosophy from Wesleyan University and his M.A. and Ph.D. in chemistry at Harvard University. Dr. Boger performed his postdoctoral research in molecular recognition in the laboratories of Nobel-prize winning chemist, Jean-Marie Lehn at the Université Louis Pasteur in Strasbourg, France.

What is Joshua S. Boger's net worth?: The estimated net worth of Joshua S. Boger is at least $124.57 million as of January 11th, 2017. Dr. Boger owns 276,225 shares of Vertex Pharmaceuticals stock worth more than $124,569,188 as of November 24th. This net worth evaluation does not reflect any other assets that Dr. Boger may own. Learn More about Joshua S. Boger's net worth.
How do I contact Joshua S. Boger?: The corporate mailing address for Dr. Boger and other Vertex Pharmaceuticals executives is 50 NORTHERN AVENUE, BOSTON MA, 02210. Vertex Pharmaceuticals can also be reached via phone at (617) 341-6100 and via email at [email protected]. Learn More on Joshua S. Boger's contact information.
Has Joshua S. Boger been buying or selling shares of Vertex Pharmaceuticals?: Joshua S. Boger has not been actively trading shares of Vertex Pharmaceuticals in the last ninety days. Most recently, Joshua S. Boger sold 8,000 shares of the business's stock in a transaction on Wednesday, January 11th. The shares were sold at an average price of $82.48, for a transaction totalling $659,840.00. Following the completion of the sale, the director now directly owns 276,225 shares of the company's stock, valued at $22,783,038. Learn More on Joshua S. Boger's trading history.
Who are Vertex Pharmaceuticals' active insiders?: Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), E. Morrey Atkinson, III (EVP), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vertex Pharmaceuticals?: During the last year, insiders at the pharmaceutical company sold shares 23 times. They sold a total of 79,177 shares worth more than $36,823,476.56. The most recent insider tranaction occured on November, 15th when EVP David Altshuler sold 15 shares worth more than $7,178.40. Insiders at Vertex Pharmaceuticals own 0.2% of the company. Learn More about insider trades at Vertex Pharmaceuticals.
Information on this page was last updated on 11/15/2024.

Joshua S. Boger Insider Trading History at Vertex Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/11/2017	Sell	8,000	$82.48	$659,840.00	276,225
1/4/2017	Sell	6,500	$77.13	$501,345.00	274,725
12/29/2016	Sell	6,500	$74.33	$483,145.00	274,725
12/21/2016	Sell	6,500	$74.16	$482,040.00	274,725
12/14/2016	Sell	6,500	$77.52	$503,880.00	274,725
11/30/2016	Sell	6,500	$83.48	$542,620.00	274,725
11/23/2016	Sell	6,500	$86.47	$562,055.00	274,725
11/16/2016	Sell	6,500	$91.55	$595,075.00	274,725
11/9/2016	Sell	6,500	$90.98	$591,370.00	274,725
11/2/2016	Sell	6,500	$77.75	$505,375.00	274,725
10/26/2016	Sell	6,500	$79.26	$515,190.00	274,725
10/19/2016	Sell	6,500	$81.84	$531,960.00	274,725
10/12/2016	Sell	6,500	$81.14	$527,410.00	274,725
10/5/2016	Sell	6,500	$87.44	$568,360.00	274,725
9/28/2016	Sell	6,500	$88.15	$572,975.00	274,725
9/21/2016	Sell	6,500	$90.82	$590,330.00	274,725
9/14/2016	Sell	6,500	$92.37	$600,405.00	274,725
9/7/2016	Sell	6,500	$95.66	$621,790.00	274,725
8/31/2016	Sell	6,500	$94.62	$615,030.00	274,725
8/24/2016	Sell	7,500	$100.46	$753,450.00	274,725
8/22/2016	Sell	1,100	$100.79	$110,869.00	268,225
8/17/2016	Sell	6,900	$99.63	$687,447.00	274,725
8/11/2016	Sell	900	$100.19	$90,171.00	268,225
8/10/2016	Sell	7,100	$100.24	$711,704.00	274,725
8/3/2016	Sell	47,000	$100.66	$4,731,020.00	274,725
7/27/2016	Sell	6,500	$95.93	$623,545.00	274,725
7/20/2016	Sell	6,500	$90.33	$587,145.00	274,725
7/13/2016	Sell	6,500	$88.81	$577,265.00	274,725
7/6/2016	Sell	5,140	$88.99	$457,408.60	273,365
6/29/2016	Sell	5,130	$84.82	$435,126.60	273,355
6/22/2016	Sell	5,130	$86.61	$444,309.30	273,355
6/15/2016	Sell	5,130	$91.18	$467,753.40	273,355
6/8/2016	Sell	5,130	$94.95	$487,093.50	273,355
6/1/2016	Sell	5,130	$93.65	$480,424.50	268,225
5/25/2016	Sell	5,130	$89.09	$457,031.70	270,414
5/18/2016	Sell	5,130	$81.18	$416,453.40	270,414
5/11/2016	Sell	5,130	$86.50	$443,745.00	270,414
5/4/2016	Sell	5,130	$81.02	$415,632.60	270,414
4/27/2016	Sell	5,130	$83.67	$429,227.10	270,414
4/20/2016	Sell	5,130	$84.10	$431,433.00	270,414
4/13/2016	Sell	5,130	$84.27	$432,305.10	270,414
4/6/2016	Sell	5,130	$89.56	$459,442.80	270,414
3/30/2016	Sell	5,130	$78.83	$404,397.90	270,414
3/23/2016	Sell	5,130	$81.38	$417,479.40	270,414
3/16/2016	Sell	5,130	$79.65	$408,604.50	270,414
3/2/2016	Sell	5,130	$91.80	$470,934.00	274,425
2/24/2016	Sell	5,130	$85.25	$437,332.50	274,425
2/17/2016	Sell	5,130	$86.93	$445,950.90	265,284
2/10/2016	Sell	5,130	$82.57	$423,584.10	265,284
2/3/2016	Sell	5,130	$90.81	$465,855.30	265,284
1/27/2016	Sell	11,200	$93.22	$1,044,064.00	265,284
1/20/2016	Sell	10,400	$93.69	$974,376.00	265,284
1/13/2016	Sell	10,400	$98.41	$1,023,464.00	265,284
1/6/2016	Sell	10,400	$121.96	$1,268,384.00	265,284
12/30/2015	Sell	10,400	$127.15	$1,322,360.00	265,284
12/21/2015	Sell	10,400	$119.26	$1,240,304.00	265,284
12/9/2015	Sell	10,400	$120.80	$1,256,320.00	265,284
12/2/2015	Sell	10,400	$130.91	$1,361,464.00	265,284
11/23/2015	Sell	10,400	$132.18	$1,374,672.00	265,284
11/11/2015	Sell	10,400	$118.59	$1,233,336.00	345,284
11/4/2015	Sell	10,400	$124.23	$1,291,992.00	345,284
10/28/2015	Sell	10,400	$119.01	$1,237,704.00	345,284
10/21/2015	Sell	10,400	$108.82	$1,131,728.00	345,284
10/14/2015	Sell	10,400	$112.62	$1,171,248.00	345,284
10/7/2015	Sell	10,400	$109.61	$1,139,944.00	345,284
9/30/2015	Sell	10,400	$103.14	$1,072,656.00	345,284
9/23/2015	Sell	10,400	$111.89	$1,163,656.00	345,284
9/16/2015	Sell	10,400	$133.24	$1,385,696.00	345,284
9/9/2015	Sell	10,400	$131.41	$1,366,664.00	345,284
9/2/2015	Sell	10,400	$125.85	$1,308,840.00	345,284
8/26/2015	Sell	10,400	$124.71	$1,296,984.00	345,284
8/19/2015	Sell	10,400	$139.93	$1,455,272.00	345,284
8/12/2015	Sell	10,400	$135.83	$1,412,632.00
7/22/2015	Sell	10,400	$130.92	$1,361,568.00
7/15/2015	Sell	12,200	$133.98	$1,634,556.00
7/8/2015	Sell	11,700	$122.74	$1,436,058.00
7/1/2015	Sell	11,700	$125.60	$1,469,520.00
6/24/2015	Sell	11,700	$130.41	$1,525,797.00
6/17/2015	Sell	11,700	$123.90	$1,449,630.00
6/10/2015	Sell	11,700	$125.02	$1,462,734.00
5/20/2015	Sell	11,700	$126.73	$1,482,741.00
5/6/2015	Sell	11,700	$122.79	$1,436,643.00
4/29/2015	Sell	11,700	$124.59	$1,457,703.00
4/22/2015	Sell	11,700	$132.46	$1,549,782.00
4/15/2015	Sell	11,700	$129.25	$1,512,225.00
4/8/2015	Sell	11,700	$123.26	$1,442,142.00
4/1/2015	Sell	11,700	$115.87	$1,355,679.00
3/25/2015	Sell	11,700	$120.76	$1,412,892.00
2/4/2015	Sell	5,700	$108.81	$620,217.00
1/28/2015	Sell	10,688	$122.78	$1,312,272.64
1/21/2015	Sell	10,500	$125.08	$1,313,340.00
1/14/2015	Sell	10,500	$120.16	$1,261,680.00
1/7/2015	Sell	10,500	$119.32	$1,252,860.00
12/22/2014	Sell	10,500	$117.65	$1,235,325.00
12/17/2014	Sell	10,500	$110.66	$1,161,930.00
11/26/2014	Sell	10,500	$114.54	$1,202,670.00
11/3/2014	Sell	127,411	$112.20	$14,295,514.20
10/29/2014	Sell	10,500	$109.44	$1,149,120.00
9/24/2014	Sell	5,200	$109.21	$567,892.00
9/17/2014	Sell	5,200	$93.62	$486,824.00
9/10/2014	Sell	5,200	$94.42	$490,984.00
9/3/2014	Sell	5,200	$92.79	$482,508.00
8/27/2014	Sell	5,200	$93.31	$485,212.00
8/20/2014	Sell	5,200	$91.51	$475,852.00
8/13/2014	Sell	5,200	$88.00	$457,600.00
8/6/2014	Sell	5,200	$86.54	$450,008.00
7/30/2014	Sell	5,200	$92.17	$479,284.00
10/29/2013	Sell	1,400	$75.42	$105,588.00
10/23/2013	Sell	1,400	$76.77	$107,478.00
10/16/2013	Sell	1,400	$75.41	$105,574.00
7/31/2013	Sell	1,400	$80.89	$113,246.00
7/18/2013	Sell	1,400	$86.12	$120,568.00
7/11/2013	Sell	1,400	$83.83	$117,362.00
7/3/2013	Sell	1,400	$80.20	$112,280.00
6/26/2013	Sell	1,400	$78.59	$110,026.00
6/19/2013	Sell	1,400	$79.11	$110,754.00
6/12/2013	Sell	1,400	$81.19	$113,666.00
6/5/2013	Sell	1,400	$77.15	$108,010.00
5/30/2013	Sell	1,400	$82.47	$115,458.00
5/22/2013	Sell	1,400	$79.72	$111,608.00
5/15/2013	Sell	1,400	$79.36	$111,104.00
12/26/2012	Sell	4,000	$41.86	$167,440.00
10/3/2012	Sell	4,000	$57.74	$230,960.00
9/5/2012	Sell	4,000	$54.70	$218,800.00

Joshua S. Boger Buying and Selling Activity at Vertex Pharmaceuticals

Vertex Pharmaceuticals Company Overview

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $450.97

$449.04

$457.54

50 Day Range

MA: $474.11

$448.01

$516.74

2 Week Range

Now: $450.97

$346.29

$519.88

Volume

1,270,384 shs

Average Volume

1,345,841 shs

Market Capitalization

$116.14 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

This company will win the AI race

From Porter & Company | Ad